Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Alteogen
Pharma
Astellas, Takeda, Chugai and more—Fierce Pharma Asia
Astellas CEO lays out the company's dealmaking plans. Takeda cuts jobs ahead of Trintellix patent expiry. Chugai seeks name recognition. And more.
Angus Liu
Jan 23, 2026 9:05am
GSK licenses Alteogen enzyme in bid to develop subQ Jemperli
Jan 20, 2026 2:26pm
Enhertu, Akeso, Fujifilm-Regeneron—Fierce Pharma Asia
Apr 25, 2025 8:45am
AstraZeneca-Alteogen, Taiho, WuXi—Fierce Pharma Asia
Mar 21, 2025 9:10am
AstraZeneca inks $1.35B deal for subcutaneous cancer drugs
Mar 17, 2025 10:55am
Daiichi enlists Alteogen for subcutaneous Enhertu in $300M deal
Nov 8, 2024 11:19am
